Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1971 1
1976 1
1984 1
1985 1
1986 1
1987 1
1989 1
1991 3
1993 3
1997 1
1998 2
1999 1
2001 1
2002 3
2003 1
2004 3
2006 1
2007 2
2008 3
2009 3
2010 2
2011 4
2012 3
2013 6
2014 5
2015 5
2016 5
2017 6
2018 6
2019 4
2020 4
2021 5
2022 4
2023 4
2024 7
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
[Postoperative cerebral dysfunction].
Tsygan NV, Odinak MM, Khubulava GG, Tsygan VN, Peleshok AS, Andreev RV, Kurasov ES, Litvinenko IV. Tsygan NV, et al. Among authors: litvinenko iv. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(4):34-39. doi: 10.17116/jnevro20171174134-39. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28617376 Russian.
Thalamic nuclei degeneration in multiple sclerosis.
Trufanov A, Bisaga G, Skulyabin D, Temniy A, Poplyak M, Chakchir O, Efimtsev A, Dmitriy T, Odinak M, Litvinenko I. Trufanov A, et al. Among authors: litvinenko i. J Clin Neurosci. 2021 Jul;89:375-380. doi: 10.1016/j.jocn.2021.05.043. Epub 2021 Jun 2. J Clin Neurosci. 2021. PMID: 34090763
[Cognitive impairment after major surgical operations].
Tsygan NV, Sandalova OS, Yakovleva VA, Ryabtsev AV, Andreev RV, Sapozhnikov KV, Odinak MM, Litvinenko IV. Tsygan NV, et al. Among authors: litvinenko iv. Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(4. Vyp. 2):74-80. doi: 10.17116/jnevro202512504274. Zh Nevrol Psikhiatr Im S S Korsakova. 2025. PMID: 40420454 Russian.
[Psychological, psychiatric and neurological aspects of COVID-19].
Chritinin DF, Shamrey VK, Litvinenko IV, Kurasov ES, Tsygan NV, Vainshenker YI. Chritinin DF, et al. Among authors: litvinenko iv. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(4. Vyp. 2):44-51. doi: 10.17116/jnevro202312304244. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37141128 Russian.
105 results